gastrointestinal, and immunologic systems, are also those which are the most sensitive to oncologic treatment. Improvement in these systems may be one of the goals for either reversing or preventing PEM.
In an initial study [9] of children with newly diagnosed advanced solid tumors and relapsed leukemia-lymphoma, anergy (as defined by the inability to respond to anyone of four recall skin test antigens) was documented in 17 of 18 patients considered malnourished. Anergy was reversed with 28 days of central parenteral nutrition support in approximately two-thirds of the patients (7/11 retested), despite continuing oncologic treatment. Van Eys et aL [17] documented significantly higher rates of infectious complications in malnourished compared with well-nourished children with metastatic disease involving bone who received parenteral nutrition support. Current data suggest that bone marrow suppression may be attenuated by parenteral nutrition support, at least in patients with stages III and IV neuroblastoma [12, 15] , patients with acute nonlymphocytic leukemia (ANLL [7] ), and patients with metastatic disease involving bone [17] . Nutritional status at the time of diagnosis of neoplastic disease has been clearly associated with outcome in adults [2] as well as children [3, 12] .
C. Childhood Neoplasms with High Risk forPEM
PEM is a common occurrence in certain high risk populations of children with neo-plastic diseases. The incidence of PEM at diagnosis of childhood neoplasms and during treatment of childhood cancer varies from 6% (children with newly diagnosed leukemia) to as high as 50% (children with newly diagnosed stage IV neuroblastoma), depending upon tumor type, stage of disease, and criteria for PEM [11] . We sequentially monitored the nutritional status (energy intakes, weights, weight for height proportionality, skinfold measurements, albumin, and transferrin) of more than 100 children with newly diagnosed neoplastic diseases during initial phases of therapy. These data formed the basis for determination of the factors that place a patient at a higher risk for the development of PEM ( Table 1 ). The tumor types usually associated with high and low nutritional risk are listed in Table 2 .
D. Staging and Assessment of Nutritional Status
In the past, states of malnutrition may have been overlooked because oflack of tangible criteria for establishing the nutritional status of these patients, or, possibly owing to an insensitivity to the significance of PEM. We developed a system for nutrition staging patients not only at diagnosis, but also during ongoing oncologic treatment because changes in nutritional status are dynamic.
I. Identification of PEM (Staging) at Diagnosis Criteria for staging patients as malnourished at diagnosis include: > 5% weight loss, weight for height < 5th percentile, or serum albumin < 3.2 g/dl. A patient who does not meet any of these criteria is staged as well-nourished. The significance of nutrition staging at diagnosis has been emphasized in a recent study [12] of 18 of our children with newly diagnosed stage IV neuroblastoma. In an equal number of malnourished and well-nourished patients at diagnosis, significantly more malnourished patients had relapsed or died by 180 days after treatment was initiated (P < 0.05). The differences in survival between the two groups of patients approached significance (P=0.08) at 1 year into treatment. The median survival of the malnourished group was 5 months compared with 12 months for the well-nourished group. It remains to be determined whether the patients considered to be malnourished at diagnosis have a more aggressive or advanced form of neuroblastoma, or, whether the nutritional status influenced the outcome.
II. Ongoing Nutritional Assessment
Dramatic changes in nutritional status have occurred over as short a period as 1 week Table 2 . Types of neoplastic disease associated with high and low nutritional risk
High nutritional risk
Stage III and IV Wilms' tumor Advanced neuroblastoma Acute nonlymphocytic leukemia Pelvic rhabdomyosarcoma Brain tumor Some non-Hodgkin's lymphomas because of the almost immediate adverse impact of oncologic treatment upon the gastrointestinal system and upon nutrient intake. The current criteria used for staging patients at diagnosis may not be sensitive enough to detect ongoing nutritional depletion.
Some pitfalls may be associated with the monitoring of weight changes as the only index of nutritional status. Children who are < 5th percentile weight for height have relatively small losses in weight compared with well-nourished children with equally low energy intakes. Malnourished children have fluid changes which mask some of the tissue wasting. Edema and dehydration may alter weight so that accurate interpretation is difficult. Furthermore, monitoring only absolute weight changes may provide a false sense of security. Weights need to be plotted sequentially on growth grids and expressed as a percentage of weight loss. For example, a 2 kg weight loss for a 60 kg teenager (3% weight loss) may not seem impressive, however, the same 2 kg loss in a 20 kg toddler represents a 10% weight loss.
Changes in weight, weight for height, and subscapular skinfold thickness are particularly useful indicators of real or impending nutrition depletion. Low energy intakes and decreases in skinfold measurements were the first indicators of nutrition depletion and occurred despite weight maintenance or a slight weight gain in several children who had no evidence of edema. Fomon and associates [5) reported a similar phenomenon in normal infants fed skim milk formula (67% of energy requirement). This group of babies experienced approximately 25% decreases in triceps and subscapular skinfold measurements even though they gained weight, albeit at a slower rate than normal.
Skinfold calipers are valuable in detecting more subtle, subclinical changes in nutritional status during early phases of treatment. Subscapular skinfold decreases > 0.3 mm correlated with low energy intakes (more than 2 standard deviations below the mean of Beal's data [1] for healthy children) in patients who initially had skinfold measurements in the normal range.
Changes > 0.3 mm are twice the coefficient of variation which was determined from 265 data sets for each subscapular skinfold measurement.
For ongoing nutritional assessment, albumin concentrations in relation to energy intake are monitored. Albumin is a useful indicator of mild to moderate PEM in some patients, i.e., decreases are seen which correspond to very low protein or energy intakes and may be observed before significant weight loss. However, albumin concentrations may be preserved at marginal or low ranges of normal (2.9-3.2 gl dl) in some children with obvious tissue wasting. Transferrin, pre albumin, and retinol binding proteins are serum proteins which may indicate subclinical PEM. They have shorter half-lives and different synthetic rates than albumin. In a current study [14] of these biochemical indicators, preliminary data strongly support the use of these serum proteins as early indicators of successful repletion.
E. Options for Nutritional Support

Enteral Nutrition
Several modes of nutrition support are available for the pediatric patient. For most children with cancer, provision of nutrients by the enteral route with oral feeding is the preferred method because treatment may last several years. An individualized feeding program which uses favorite, nutritious foods of the child during treatment-free periods has numerous practical and psychologic advantages over parenteral nutrition. These include a lower risk of infection and other catheter-related complications, more normal play activities and life-style, and a positive way for parent and child to be involved in their own care. In addition, enteral feeding is more economic. In our experience, however, this type of enteral feeding program has not been effective in either preventing or reversing PEM in most of the patients at high nutritional risk during initial intense treatment. In a study [9] of 21 children with advanced cancer who were enterally nourished, energy intake was very low, averaging 48% + 24% of the Recommended Dietary Allowances (RDA) for kilocalories, and weight loss averaged 16% in less than 1 month of treatment. Similarly, in a recent study of 32 children with stages III and IV neuroblastoma [15] significant loss of fat reserves and weight occurred during the initial 28 days of treatment when enteral nutrition alone was provided. The children who became malnourished were unable to make nutritional gains thereafter, despite numerous delays in treatment.
We feel that the use of nasogastric tubes to provide nutrition is contraindicated in the older infant, toddler, and preschool age groups of children because of psychologic trauma associated with the insertion and maintenance of tubes. Nausea and vomiting in addition to decreased intestinal motility and absorption from oncologic therapy make this modality less favorable and less effective. Gastrostomy feedings also seem to be of limited value for similar reasons. In a few older schoolage and teenage children, continuous nasogastric nighttime feedings have been beneficial.
II. Parenteral Nutrition
Nutritional and Immunologic Benefits
Parenteral nutrition is both safe [18, 13] and efficacious in children with neoplastic diseases. In a group of 28 patients who had stage III or IV solid tumors or second relapse leukemia-lymphoma, the effectiveness of central parenteral nutrition (CPN) in reversing PEM and restoring immunity was documented [9] . Of the 28 patients who were malnourished, 20 received CPN for a mean of 24 days (average caloric intake of 90% of the RDA during weight gain). Initially, patients were randomized to either 10 or 28 days of CPN. The lO-day randomization was abandoned after the initial three patients rapidly returned to their initial malnourished state because of continuing oncologic treatment. Review of data from 20 patients who received longer intervals (> 28 days) of parenteral nutrition indicated that shorter intervals (9-14 days) did not restore an appropriate weight for height (though weight gains were significant) nor fat reserves, and, did not return serum albumin concentrations to > 3.2 gl dl. Despite the failure of shorter intervals of 140 parenteral nutrition to reverse PEM, an improvement in transferrin concentration occurred, suggesting that transferrin was more responsive than albumin. Another short-term benefit was a significant improvement in the child's general state of well-being. A period of 28 days CPN restored weight for height percentiles, subscapular skinfold percentiles, albumin, and transferrin concentrations to normal values. Curtailment of parenteral nutrition support before reversal of PEM and completion of intensive oncologic support reduced the benefits of previous nutrition support. Therefore, we recommend continuing the parenteral nutrition support for several days beyond cessation of chemotherapy or irradiation treatment which induce anorexia, nausea, and vomiting. Nutritional benefits from effective parenteral nutrition support are maintained after completion of the intense treatment, unless complicating factors in the patient's clinical course such as relapse, sepsis, or major abdominal procedures occur [10, 15] .
In a recent study [13] comparing the effectiveness of parenteral nutrition provided by either central or peripheral veins, the central line allowed provision of greater concentrations of glucose and obviated problems with subcutaneous peripheral infiltrations. In 19 children with advanced neuroblastoma or Wilms' tumor, both routes of administration were effective in reversing PEM when adequate energy and protein were provided over a 21-to 28-day period. Significant increases in anthropometric measurements and albumin were similar for the two groups. Both groups had a similar incidence of anemia, fever episodes (with and without documented sepsis), and mildly elevated SGOT concentrations. The peripheral parenteral nutrition (PPN) group, however, had a high incidence of line changes associated with peripheral infiltrations and related psychologic trauma. In this study, the effectiveness of PPN was dependent upon an oral intake which provided an average of 30% additional energy to meet the RDA. Based upon these results, a central line is used for our standard parenteral nutrition support program and a peripheral line for periods when the central line is interrupted.
Treatment Tolerance Benefits
Treatment tolerance benefits from parenteral nutrition compared with oral nutrition have been documented in several recent prospective randomized studi~s .. of children with specific tumors. In an mitlal report of a randomized study [12] of 17 patients with stage IV neuroblastoma, those who had a favorable nutrition course during the first 21 days of therapy had significantly fewer treatment delays (secondary to absolute granulocyte counts > 1000/IlI or platelets > 75 OOO/IlI) and fewer drug dose reductions throughout the first 10 weeks of treatment. Treatment consisted of 5-day cycles of OTIC, vincristine, an~ cyclophosphamide given at 3-week mtervals. The treatment tolerance benefits from effective reversal or prevention of PEM were further documented in 32 patients with stages III and IV neuroblastoma [15] .
Three other prospective randomized studies of children with cancer have also documented treatment benefits from CPN compared with oral nutrition in improving tolerance to chemotherapy [17] , in improving adherence to chemotherapy schedules [6] , or in accelerating recovery of normal marrow function [7] . In contrast to these findings, Shamberger et al. [16] failed to document benefit from CPN compared with oral nutrition in improving recovery from bone marrow suppression in a series of 27 young patients who received extremely aggressive treatment f?~ po.or l?rognosis sarcomas. In a muiti-mstltutlonal study [4] of 25 patients who received abdominal irradiation, the CPN and oral nutrition groups of patients did not differ in ability to adhere to the radiotherapy schedule. Thus, the value of CPN in improving treatment tolerance probably relates to certain types and stages of tumors as well as specific treatment.
Complications and Limitations
Complications can be minimized or safely controlled with careful patient management and strict adherence to a parenteral nutrition protocol. In a multi-insti~utional study of complications of adults wIth cancer randomized to either CPN (125 patients) or control groups (126 patients),
Mullen [8] reported that CPN adds little serious morbidity and mortality. An increased incidence of fever (P < 0.003), anemia (P < 0.09), and pulmonary dysfunction (P < 0.12) was documented in the CPN group, however, incid~nce o! documented infections (25%) at dIstant sItes was similar for both groups.
The possibility that CPN stimulates .tumor growth in excess of host repl.etlOn needs to be considered, although chmcally this has not been observed when aggressive oncologic treatment is given simultaneously. In fact, it is conceivable th~t CPN may beneficially stimulate cell replIcations and increase effectiveness of cellcycle-specific drugs. Certainly, tumor ~e sponse may be improved when effectlve oncologic treatment is completed on schedule.
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